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Transcriptomics has been extensively applied to the investigation of the CHO cell platform for 
the production of recombinant biotherapeutic proteins to identify transcripts whose expression 
is regulated and correlated to (non)desirable CHO cell attributes. However, there have been 
few attempts to analyse the findings across these studies to identify conserved changes and 
generic targets for CHO cell platform engineering. Here we have undertaken a meta-analysis 
of CHO cell transcriptomic data and report on those genes most frequently identified as 
differentially expressed with regard to cell growth (µ) and productivity (Qp). By aggregating 
differentially expressed genes from publicly available transcriptomic datasets associated with 
µ and Qp, using a pathway enrichment analysis and combining it with the concordance of 
gene expression values, we have identified a refined target gene and pathway list whilst 
determining the overlap across CHO transcriptomic studies. We find that only the cell cycle 
and lysosome pathways show good concordance. By mapping out the contributing genes we 
have constructed a transcriptomic µfingerprint¶ of a high-performing cell line. This study 
provides a starting resource for researchers who want to navigate the complex landscape of 
CHO transcriptomics and identify targets to undertake cell engineering for improved 
recombinant protein output. 
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The most widely industrially utilised mammalian cell expression system for the manufacturing 
of biotherapeutic proteins is the Chinese hamster ovary (CHO) cell. The CHO cell expression 
system has now been used for the manufacture of a number of classes of biotherapeutic 
proteins, notably monoclonal antibodies (mAbs) [1], however there remains the potential to 
further optimise this system, particularly for the expression of novel format and difficult to 
express molecules. The appeal of the CHO cell for the manufacture of biopharmaceuticals is 
explained by several factors. First, CHO cells have been in use as protein expression 
µIDFWRULHV¶ for several decades, meaning there is an established precedent to using this system 
and a track record of approval from regulatory agencies. Secondly, CHO cells have 
appropriate specific productivity, can grow in suspension in chemically defined, serum-free 
media [2]. CHO cells can now deliver high recombinant product yields, with reports of 
recombinant antibody yields of >10 g/L compared to other systems such as HEK 293 where 
yields of approximately 1 g/L have been reported [3,4]. They also have the ability to produce 
human like glycosylation patterns that are bio-compatible with the human immune systems 
[5]. However, the CHO cell research is still being driven by a need to reduce development 
times (and costs), increase recombinant protein yields/quality, enhance cell growth and 
express novel molecules.  
CHO cell research is presently experiencing a paradigm shift in terms of how the cell 
factory is understood due to the availability of a variety of omics data. The Chinese hamster, 
CHO K1 [6] and various other cell line genomes have been sequenced and published along 
with a library of proteomic, transcriptomic and metabolomic data [7±9]. These studies and 
databases provide the community with a wealth of information around the CHO cell platform 
and allow for the rational and precise fine-tuning of the CHO recombinant protein expression 
platform. However, in order to identify pathways and targets for CHO cell engineering, the 
investigator needs to know what genes are being expressed under which conditions and how 
this affects phenotype. Investigations into the CHO transcriptome have been underway since 
2006 [10] using in house CHO cDNA microarrays and cross-species microarrays. More 
recently, RNAseq as a technique has been applied to CHO transcriptomics, with the first 
reports in 2010 [11]. According to the CHO bibliome [12] up to 2015, 52 CHO gene expression 
and transcriptomic publications had been identified with datasets being generated for panels 
of CHO cell lines with different growth and production characteristics [13,14], under cold shock 
[15], butyrate treatment [16], adaptation to suspension [17] and other culture conditions 
[18,19]. Here we describe a meta-analysis of different CHO transcriptome datasets to identify 
common pathways and genes identified as underpinning CHO cell growth and product yield. 
These genes and pathways represent priority targets for cell engineering and manipulation to 




2.1 Identification of Publicly Available CHO Transcriptomic Datasets for Analysis  
The CHO bibliome [12] was used to identify CHO based transcriptomics publications up to 
2015. Additional datasets sourced from those published 2015 ± 2017 were also included in 
the analysis. The list of final genes and their datasets of origin are provided in Table 1 and 
Supplementary Table 1. Transcriptomic studies that used a cross-species microarray 
approach were omitted since the accuracy of cross-species microarray data is still under 
debate. From these datasets, we extracted lists of differentially expressed genes and assigned 
them to one of two groups based on their association with either specific productivity (Qp) or 
growth (µ). This was undertaken in order to accurately discern the impact of genes to a specific 
phenotype as it has been shown that Qp can come at the cost of µ and vice versa [20]. An 
expression value (+1 or -1) was assigned to all genes and corresponds to the upregulation 
(+1) or downregulation (-1) of the gene. This did not consider the absolute fold change in the 
datasets, only the direction in which expression changes were observed. Comparing fold 
change values across datasets without having access to the raw data of the omics experiment 
would not be meaningful and, unfortunately, such data is not available from most of the 
datasets included in this study.  
After the assembly of an aggregate gene list, two parameters were calculated for unique gene 
entries in the Qp and growth categories: 
a) Frequency - the number of times a gene appears across selected datasets. 
b) Concordance - the arithmetic mean of expression values (from the assigned -1 or +1 
expression value assigned as described above). A concordance threshold of -0.2 and 0.2 was 
established to differentiate which genes show an agreement in expression data. This 
corresponds to a minimum of three fifths 0.6 of the gene entries in the group having an 
agreement of the expression value. 
These two parameters form the cornerstone of our analysis. 
2.2 Ensuring Consistent Gene Annotation for Analysis 
Most of the available publications have annotated the gene sets as mouse, rat or human gene 
,'¶VRUE\XVLQJ official gene symbols. To compare the different gene lists all datasets had to 
be re-annotated to a single format so that these could be compared and analysed. Re-
annotation was performed using the Mouse Genome Information database batch gene lookup 
tool (http://www.informatics.jax.org/batch) into an Entrez ID format. This format is preferable 
to an official gene names based annotation because gene name designations tend to change 
with time and may cause duplications of genes under synonym entries. ,'¶V LGHQWLILHG DV
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pseudogenes and non-coding genes were discarded. (QWUH],'¶VJLYHQLQSXEOLFDWLRQVZHUH
not changed. The annotated master gene list is provided in Supplementary Table 2.  
2.3 Pathway Enrichment Analysis 
For pathway enrichment, eQWUH] ,'¶V RI JHQHV with a frequency of 1 in the growth and 
productivity groups (GG, PG) were rejected and these genes account for roughly half of the 
master gene list. Entrez ,'¶VRIJHQHVthat had a frequency of t2 were submitted to DAVID 
Knowledgebase 6.8 (https://david.ncifcrf.gov/) for functional annotation analysis with the 
option to chart KEGG pathway enrichment as we wished to identify conserved differentially 
expressed genes across CHO cell lines and conditions. KEGG was used as the functional 
annotation database because the use of KEGG in pathway enrichment is widespread for 
interpreting the biological meaning of transcriptomic datasets and is well curated [16,21,22]. 
Default functional annotation parameters were used (Threshhold count 2 and EASE value of 
0.1). Pathway charts were generated in DAVID using the KEGG database. We then included 
an overlay of concordance values for each gene present in the meta-analysis and in the 
pathway enrichment to visualise the dynamics of pathway expression. Once the gene list was 
submitted to DAVID, the number of viable targets was reduced due to insufficient coverage in 
the database. At the time of undertaking this study, 7720 genes were present in the KEGG 
pathways for Mus musculus. 
3.0 Results 
3.1 The datasets used in this study 
We wanted to screen the publicly available CHO transcriptomic data to aggregate and analyse 
patterns of changes at the transcript level relating to high specific productivity (Qp) and growth 
rate (P). The working datasets used in this study consisted of publicly available species-
specific transcriptomic data that was generated using CHO cell lines expressing recombinant 
proteins under various conditions. The reported transcriptomic experiments were set up using 
a number of different approaches. Some experiments compared a panel of cell lines with a 
range of parameter values, while in others cells were exposed to known productivity or 
phenotype changing treatments such as cold shock or sodium butyrate to enhance their 
recombinant protein yields or change cell growth. The selected publications for data mining 
are presented in Table 1. Out of the 19 datasets, only 4 used RNAseq while 2 compared the 
use of RNAseq to a microarray in the same experiment. Affymetrix based custom microarrays 
are the most often used across the datasets. In the Qp group, 2 studies used copper to reduce 
lactate levels while 4 studies used butyrate to enhance Qp. One dataset was generated under 
high osmotic stress and 4 induced cold shock in the culture. Six of the studies directly 
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investigated the differences in transcriptomic gene expression amounts between cell lines with 
different Qp. In total, we assigned 16 lists to the Qp category and 6 to growth. Growth datasets 
included in this study compared a panel of cell lines with different growth characteristics ± no 
growth enhancing processes were used in any of the sources. Lists from 3 sources are present 
in both groups because they contained data that was partitioned for these phenotypes 
separately. Genes present in these lists were then assigned values for their frequency and 
concordance as outlined in section 2.1. The top most frequent genes across the datasets (5) 
are listed in Table 2 along with their individual concordance values. We note that definition of 
Qp DVµKLJK¶GLIIHUVEHWZHHQVWXGLHVDQGLVDVXEMHFWLYHMXGJHPHQWPDGHE\WKHLQYHVWLJDWRUV
of each study. 
Taking into account the clonal variation of the cell lines used in the datasets is also important. 
These are included in the supplementary file S1. We can see that the dominant cell line was 
CHO-DXB11, which was used in 8 studies. These cells are DHFR deficient so that MTX can 
be used as a selection tool. DHFR deficient cells were used in 11 of our 19 studies. 
Unfortunately, 7 studies failed to self-report the type of CHO cell line they were using. 
3.2 Pathway enrichment analysis 
We set out to determine whether particular pathways were enriched within the lists that we 
extracted from the datasets. It has been suggested that single gene overexpression or knock-
down alone is unlikely to govern complex changes underpinning phenotypes such as growth 
or recombinant protein yield [23], except in cases where a cell line has a specific bottleneck 
or a product specific requirement. On-the-other-hand, groups of genes (or pathways) can be 
co-expressed together with moderate fold change values [24], where the cumulative 
contribution effect results in an improvement in the phenotype required (growth, productivity). 
Thus, in a cell line engineering strategy, changes at the transcriptomic level that reflect (a) 
high value single gene targets, (b) global transcriptomic analysis of groups of genes that are 
co-expressed, and (c) entire pathways that are enriched within the expression data, should be 
considered.  
To analyse the results from the selected transcriptomic studies, the differentially 
expressed gene lists from these sources were aggregated and analysed for frequency and 
concordance of expression direction. In total, 4783 unique differentially expressed genes were 
identified (4044 Qp and 1406 growth associated as visualised in Figure 1a.). Between these 
groups, an overlap of 667 genes was established. The frequency distributions for these groups 
are reported in Table 3. A detailed annotation master list reporting on the frequency, direction 
of expression and concordance of discovered genes across the datasets analysed here is 
provided in Supplementary file S2. The results from the pathway enrichment analysis using 
KEGG pathways data are presented in Table 4 and are more extensively described and 
7 
reported in the Supplementary Tables S3 & S4. We have integrated these enrichment results 
onto pathway maps, which enables a more integrative look at the interactions between the 
genes identified.  
From the pathway enrichment analysis, a number of what might be considered 
µunusual¶ pathways were identified including biosynthesis of antibiotics and Epstein-Barr (EB) 
virus infection. This can be explained by the fact that these pathways share a broad overlap 
with other major pathways. In the case of the EB virus infection pathway, half of the genes 
assigned are present in the cell cycle, while almost all hits in the biosynthesis of antibiotics 
pathway term are present in the general cell metabolism pathway. Therefore, we deemed 
these pathways as being non-specific and they were excluded from further considerations for 
identification of potential cell engineering targets. We have kept these non-specific pathways 
in the list to reflect a typical enrichment result and for reference, should anyone try to replicate 
or use our work in the future. 
For those genes associated with the growth group, we observed that only a small 
number of relevant pathways were found to be enriched; the cell cycle, phagosome and 
lysosome (Benjamini-Hochberg adj. p-value <0.05). The cell cycle (0.42) and lysosome (-0.73) 
pathways had high concordance within the data sets, while there was little concordance in the 
phagosome (-0.02) pathway for the genes being up- or down-regulated. In comparison, the 
only pathway that showed concordance in the Qp group was the lysosome (-0.36). The overlap 
between genes in these two pathways (cell cycle and lysosome) for both groups is shown in 
Figure 1B & 1C. In both cases, there were more genes in the Qp group for both pathways; 22 
and 25 respectively for lysosome and the cell cycle. This is most likely a result of the fact that 
the Qp group is larger, therefore has more coverage of the pathways. We have used the 
pathway enrichments to explain changes in cellular mechanisms that could lead to fast growth 
or high specific productivity phenotypes and also compared genes identified in the study with 
engineering strategies that others have applied to engineer increased yields in recombinant 
CHO cell lines. The pathways are presented in more detail in the following sections. 
3.3 Cell cycle pathway 
The pathways that show the most concordance are presented in more detail in Figure 2. There 
are several functional clusters of genes in the KEGG cell cycle pathway that are present in the 
enrichment data. One such group is clustered around P53 - one of the most studied genes in 
the VFLHQWLILF OLWHUDWXUHGXHWRLWVVWDWXVDV WKH³JXDUGLDQRIWKHJHQRPH´ and 3¶V role in 
controlling the DNA damage checkpoint [25]. MDM2 directly binds to P53 SUHYHQWLQJ LW¶V
mechanism of action; MDM2 shows a strong downregulation concordance in the growth group 
(GG) and no concordance in the productivity group (PG), while P53 is upregulated. P53 is 
known to be mutated in CHO-K1 cells and facilitates DNA repair but not UV-induced G2/M 
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arrest or apoptosis [26]. It is unclear how expression of P53 helps promote cell growth. 
Interestingly, the transcripts that code for proteins that lead to growth arrest as a response of 
p53 upregulation (GADD45A and P21 (CDKN1A)) both show downregulation with good 
concordance. GADD45A and P21 can interact with PCNA to initiate DNA damage repair 
response and inhibit transition into S-phase [27,28]. P130(RBL2) is known to interact with 
proteins of the EF2 family as part of a UV-induced DNA damage repair pathway to cause cell 
cycle arrest [29] and was strongly downregulated in the PG. On-the-other-hand, CREBBP 
(EP300) is upregulated in the PG even though it is DWXPRXUVXSUHVVLQJJHQHEHFDXVHRILW¶V
ability to activate P53 through acetylation [30]. Based on this it seems that the mechanisms 
associated with DNA repair growth arrest are inhibited in the GG while PCNA is upregulated 
due to its role in DNA synthesis as a processivity factor. The MCM genes are upregulated with 
strong concordance in the GG as well. MCMs together form a hexamer that acts as a helicase 
essential for the function of the replication fork in DNA synthesis [31]. MCM7 is also found 
upregulated in the PG. However, MCM5 and MCM3 are downregulated. It has been observed 
that overexpression of MCM3 leads to inhibition of the G1/S checkpoint, while knockdown 
does not affect the entry or progression of said checkpoint [32]. MCM5 knockdown leads to S-
phase arrest in CHO cells and overexpression was shown to prevent over-duplication of 
centrosomes [33]. Based on available data it is not clear how downregulation of these two 
genes would contribute to an increased Qp phenotype. DNA-PK(PRKDC) is known to be an 
upstream activator of p53 and the knockdown phenotype is known to be sensitive to UV 
irradiation is downregulated in the PG group as well [34]. MYC was found to be upregulated 
in the GG, which is not surprising as it is a characterised oncogene that promotes DNA 
synthesis and has been implicated in DHFR/MTX associated gene amplification [35]. 
Another cluster of genes appears to be involved in the entry/exit of the mitotic stage of 
the cell cycle. Cyclin B1 signals the irreversible start of cell division and CDC20 is responsible 
for activating the APC complex which degrades G2/M cyclins and signals start of anaphase, 
while MAD2 stalls the separation of the chromosomes until they are properly aligned [36]. All 
three of these genes showed upregulation with strong concordance in the GG as well as 
YWHAE/14-3-3 H, which binds CDC25 proteins based on their phosphorylation state 
preventing a premature entry into mitosis before replication of the genome [37,38]. While the 
Cyclin B2 gene was found to be upregulated in the PG, CDK1 was downregulated. Typically, 
CDK1 downregulation is associated with a prolonged G2/M phase and it has been proposed 
that CDK1 can have an inhibitory effect on the secretory pathway which would decrease Qp 
[39,40]. PLK1 is upregulated in the PG which activates the CyclinB/CDK1 complex and the 
APC. This is supported by upregulation of CDC20 in both groups. BUB1B is downregulated in 
Qp and inhibits the APC and PLK1 [36,41]. However, CDC27 which is a core subunit of the 
APC and responsible for ubiquitin mediated degradation of B-Cyclins and degradation of 
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CDC20 [42], is downregulated in the PG. Our meta-analysis therefore suggests that the cell 
cycle in CHO cells can be rewired in three major ways related to increased growth; 
upregulation of proteins that facilitate the passing of the G1/S checkpoint, upregulation of DNA 
synthesis and those that assure proper separation of chromosomes in the anaphase.  
A number of cell cycle based engineering strategies have been attempted in CHO cells 
that provides further evidence that this pathway has potential for engineering to improve 
desirable phenotypes. MDM2 was overexpressed in batch cultures increasing viable cell 
concentration two times over control cells in spent media conditions [43]. GADD45A was used 
to arrest the cell cycle via inducible expression controlled by doxycylin in CHO-TREx, showing 
a 110% increase in yields of Fc fusion protein Valpha [44]. Overexpression of CDC20 in CHOd 
cells led to a 4-fold increase in the VCD of cells growing on plates by day 14 compared to cells 
transfected with antisense CDC20 cDNA. The antisense cells also grew larger and had more 
DNA per cell as shown by flow cytometry [45]. A small molecule inhibitor of CDK4/CDK6 was 
able to induce sustained G1/S checkpoint arrest for up to 4 days without causing cell death or 
decrease of product quality. As a result Qp was increased ~2 fold across a panel of cell lines 
[20]. One of the most obvious candidates to induce cell cycle arrest are the cyclin dependant 
kinase inhibitor proteins. Fusseneger et al. has successfully overexpressed P21 along with 
CCAAT/enhancer-ELQGLQJSURWHLQĮE\ WHWUDF\FOLQHHQKDQFLQJ WKH\LHOGVRI6($3E\-15 
times [46]. The overexpression of BCL-XL with P27 was found to significantly increase SEAP 
yields in the same study. A similar method was applied to overexpression of CDKN1B with 
comparable results to P21 overexpression induced cell cycle arrest [47]. E2F-1 was 
overexpressed in CHO-K1 cells leading to elevated cyclin A levels and bypassing the need for 
serum in the growth media [48]. Similar effects have been observed in CHO-K1 by 
overexpression of cyclin E [49]. Overexpression of CDC25A and CDC25B has successfully 
been used to increase recombinant protein yields as well, however cell lines displayed an 
increased incidence of chromosomal aberration [50]. Finally, MYC has been stably 
overexpressed in both suspension and adherent cells resulting in increased growth rate and 
VCD [51]. 
3.4 Lysosome pathway analysis 
The KEGG lysosomal pathway graphic provides an overview of the progression of endosome 
maturation and genes belonging to the pathway are roughly classified based on their functions. 
Cathepsins are some of the most vital proteins in the degradation and recycling machinery of 
the lysosome. Of these, CTSL (GG, PG) and CTSA (GG) were found to be downregulated. 
CTSL knockout mice have been shown to have hyperproliferation of hair follicle epithelial cells 
and basal epidermal keratinocytes [52]. Cathepsins have also been implicated in mAB 
degradation during production from CHO cells via proteomic analysis [53]. 
Glycosylceramidase gene GBA was found to be downregulated and quite a few sphingolipid 
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metabolism genes can be seen within the Qp group - ceramide synthase (CERS2) and 
sphingosine-1-phosphate (SP1) lyase-1 (SGPL1), alkaline ceramidase 3 (ACER3) were 
downregulated, while SGPHK1 was upregulated. This suggests an overall trend towards 
downregulation of ceramide levels and an increase in sphingosine-1-phosphate. Ceramide 
has been implicated in promotion of apoptosis, while S1P induces proliferation in HEK293 
cells [54]. Yusufi et al. reported DQLQFUHDVHLQWKHOHYHOVRIFHUDPLGHDQGLW¶VGHULYDWLYHVLQa 
high producing SH-87 cell line when compared to the host cell [55]. Another two genes 
involved in sphingolipid metabolism coding sphingoOLSLG DFWLYDWRU SURWHLQV 6$3¶V ZHUH
downregulated in the PG; prosaposin (PSAP) and GM2 ganglioside activator (GM2A). These 
genes are responsible for degrading lysosomal membrane bound glucocerebrosides. 
Accumulations of these lipids can lead to Gauche disease and are linked to mutations in PSAP 
and GBA, while GM2A deficiency is implicated in GM2 gangliosidosis [56]. These genes are 
mainly studied in neuronal context and their role in CHO cell metabolism in not clear. 
The major lysosomal genes LAMP1 and LAMP2 were downregulated in both groups 
and represent some of the most frequent hits across the meta-study; 6 and 5 respectively. 
Lysosomal content has been shown to be negatively correlated with Qp in a tissue 
plasminogen producing CHO cell line along with LAMP2 mRNA levels. The study also reported 
that glutamine depletion on its own is enough to increase levels of autophagy [57]. The 
Niemann-Pick type C1 NPC1 gene was downregulated in the GG; CHO cells lacking NPC1 
have been observed to have impaired lipid recycling, accumulating in late endosomes. 
However, no data was given on any impact on cell growth [58]. LAPTM4A was found to be 
downregulated in both groups. Little is known about this protein, except that it is a 
transmembrane protein localized to the lysosome and possibly facilitates transport across the 
membrane. It has been shown to co-precipitate with NEDD4, which was upregulated in growth 
and downregulated in the PG with a cumulative frequency of 7 across both groups. NEDD4 
deficient mice seem to divert LAPTM4 from the lysosome towards the plasma membrane [59]. 
CLN5 is downregulated in the PGEXWLW¶VH[DFWIXQFWLRQLVQRWZHOOXQGHUVWRRG'HSOHWLRQRI
CLN5 has been shown to degrade lysosomal sortilin receptors and cation-independent 
mannose 6-phosphate receptors (CI-MPR) [60]. CLN5 null human fibroblast cells were 
observed to have decreased levels of ceramide, sphingomyelin and glycosphingolipids along 
with increased growth and apoptosis. Based on these findings it was proposed that CLN5 has 
a function in the de novo synthesis of sphingolipids [60]. Clathrin light chain a (CLTA) was 
found to be upregulated in growth but downregulated in the productivity group. Clathrin is a 
key protein in vesicle formation and has an essential role in endocytotic trafficking and protein 
secretion [61]. It has been shown that MAD2B is co-localized with CLTA at the mitotic spindle 
for stabilization of kinetochores. MAD2A was also found to be upregulated in the growth group 
as part of the cell cycle pathway suggesting a possible explanation for inclusion of CLTA in 
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the GG, but not the PG [62]. The GGA family genes were implicated in both PG and GG; 
GGA2 was downregulated in both and GGA3 upregulated in the GG. GGA depletion has been 
shown to have a missorting effect on mannose-6-phosphate receptors, cathepsin D and APP 
secretory inhibition [63,64], which was one of the top hits in our master gene list. In HeLa cells 
LWZDVIRXQGWKDWRYHUH[SUHVVLRQRI**$¶VLQFUHDVHVIUDJPHQWDWLRQDQGYDFXROL]DWLRQRIWKH
trans-Golgi network implying that these proteins have a role in maintaining Golgi integrity [65]. 
Genes coding for the į and ȝ subunits of AP-3 were found to be downregulated in the PG. 
AP-3 has been shown to regulate LAMP1 and LAMP2 sorting into late endosomes/lysosomes 
and knockdown of AP-3 led to an increase in LAMP proteins in tubular endosomes and on the 
cell surface [66]. In HEK293 cells depletion of AP-3 was shown to have an impact on lysosomal 
distribution, causing them to accumulate at the end of microtubules in the peripheral cytoplasm 
[67]. 
Both the regulatory profiles of the PG and GG point towards a clear pattern of downregulation 
of lysosomal activity by disrupting trafficking and recycling of lysosomal proteins and structural 
lipids and impairing lysosomal processing. None of these proteins have been engineered in 
recombinant CHO cells, however strategies to induce autophagocytic and supress lysosomal 
pathways have been implemented before using inhibitors as described in Kim et al. with up to 
30% increase in recombinant mAB yields [68].  
 
4.0 Discussion 
4.1 Evaluation of publicly available datasets 
Of the data investigated, only two data sets/publications report on the application of RNAseq 
to investigate transcriptomic changes associated with Qp and growth rate. Studies comparing 
RNAseq and microarray approaches suggest that the two techniques can complement each 
other. Birzele et al. reported expression data for 10428 genes in a microarray group and 13375 
genes in an RNAseq group [11]. Between these approaches there was an overlap of 8404 
genes with 2024 and 4971 unique genes in the microarray and RNAseq groups respectively 
[11]. On-the-other-hand, Yuk et al. reported that there was almost no overlap between 
differentially expressed genes identified by microarray and RNAseq [69]. In this study, 
samples were taken at different times through culture at 4 and 48 h, and the subsequent 
microarray and RNAseq data sets had only 1 gene in common. This is surprising as it has 
been shown that RNA-seq and microarrays can have a high degree of concordance on the 
same biological system [70]. Whilst microarrays can give a good indication of relative 
expression levels of genes in a given experiment, these studies cast doubt on the ability of 
single transcriptomic analysis platforms to provide us with a representative snapshot of the 
transcriptome and hence a wider surveying and compiling of multiple studies may provide a 
better insight into those cellular processes important during CHO cell bioprocessing.  
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Combining omics approaches is a potentially powerful approach for constructing multi-
dimensional and comprehensive models of CHO cell biology [7]. However, to date undertaking 
such an approach has not been widely applied in comparative cell line analysis to investigate 
the underlying changes in cellular machinery. The work reported by Yusufi et al. [55] is one 
such noteworthy attempt to compare a parental CHO-K1 cell line with an antibody producing 
derivative. In this work, not only are changes in mRNA levels, but also copy number variant 
changes, reported and analysed. Using DAVID enrichment, they identified groups of genes 
enriched after differential expression analysis. Among these were genes involved in DNA 
damage repair, mRNA processing and transport, vesicle transport and mitochondrial 
metabolism. Some of the genes singled out in this report [55] were also identified in the meta-
analysis undertaken and reported here including Mmp14, Tm9sf2, Slc1a4, cers2, lpin1, rps2, 
Hnrnpa1, Nsmce2, Ercc1 and Eps8. We also note that when comparing transcriptomic 
datasets some overlap can be missed and our study does not account for this nuance. This 
emphasises the need for enrichment analysis as different sets of stochastic transcriptomic 
changes can identify similar changes at a pathway level. 
4.2 Limitations of the meta-analysis 
Using aggregation methods and pathway enrichments, we present a meta-analysis of CHO 
high Qp and growth transcriptomics. However, it should be noted that the ability of a meta-
analysis to identify common features and differentially expressed genes is highly dependent 
on the quality of the data available. In the case of the data that have been investigated here, 
there are several limitations for a meta-analysis. The most obvious limitation was the lack of 
accessibility to the transcriptomic platform expression data e.g. probe intensities for 
microarrays and raw RNAseq data [71]. Out of the 4 available published RNAseq datasets, 
only 1 has made the raw RNAseq data available, and only 2 of the microarray based 
transcriptomic studies have deposited their raw microarray data in public databases. This is 
RXWRIVWHSZLWKJHQHUDOO\DFFHSWHGJRRGSUDFWLFHIRUDFFHVVLELOLW\RIµRPLF¶W\SHGDWDZKHUHE\
the scientific community can only use and review/judge such reports if the raw data (as 
opposed to analysed data) is made available. This situation is exacerbated in the CHO cell 
field as the majority of the microarrays used in the experiments published are listed as 
proprietary and their probe sets are not disclosed. Further, the unavailability of the raw 
transcriptomic data prevents reanalysis of the data by others in the field, integration with other 
datasets or the reader reproducing any of the analysis or statistical outputs reported. 
Differential gene expression fold changes and listed p-values cannot be meaningfully 
compared between different studies due to experimental and biological variation. In our master 
gene list, around half of the genes appear only once across the 19 transcriptomic datasets as 
differentially expressed, which is indicative of a highly heterogeneous dataset to begin with.  
13 
To complicate meta-analyses further, there is a high degree of variance between the 
experimental methods of transcriptomic analyses performed. Further, the datasets reported in 
the literature around CHO cell biology are analysed using dramatically different workflows 
ranging from partial least squares regression [14], to co-expression clustering [24] and gene 
set enrichment analysis [13]. Naturally, these methods tend to produce gene lists that are 
derived from different methods of analysis and format, making it difficult to aggregate and 
interpret results across datasets. In human and mouse, a wealth of easily accessible and 
comparable transcriptomic data is available in data repositories like the Gene Expression 
Omnibus (GEO, see https://www.ncbi.nlm.nih.gov/geo/), which requires depositing MIAME 
(Minimum Information About a Microarray Experiment) compliant information transcriptomic 
datasets from investigators (including raw data file for each hybridization, processed data, 
annotation information, experimental design, gene identifiers and other annotations, data 
processing protocols) and facilitates target identification under specific conditions for further 
research.  
In the CHO cell field, while there are now a number of transcriptomic data sets 
generated and publicly available, very few studies actually follow up on their results and 
validate transcriptomic findings. In one of the few instances where such work has been 
undertaken, out of 21 potential targets from a transcriptomic and proteomic analysis of a CHO 
K1 cell line, 5 targets were selected for further validation [72]. Only one of these 5, VCP, had 
a substantial effect on CHO cell growth. This is not unexpected as it is well known that 
transcriptomic data does not always correlate to abundance of protein [73] making validation 
a cumbersome ordeal. However, in order to build more comprehensive multi-omic models the 
CHO cell community should strive towards not only the generation of high quality omics data, 
but more high-throughput rigorous validation, so that a comprehensive understanding of the 
cell and potential engineering strategies can be developed. This study here will help provide 
a framework for researchers looking to interpret the currently available transcriptomic datasets 
DVDµZKROH¶DQGZDQWWRDSSO\WKHILQGLQJVIRULPSURYLQJWKH&+2FHOOSODWIRUP7KHSDWKZD\s 
and genes identified as high frequency differentially expressed genes await validation by 
others as potential targets for achieving enhanced cell growth and/or productivity of 
recombinant biotherapeutics from cultured CHO cell expression systems.  
5.0 Conclusions 
In this study, currently available CHO transcriptomic datasets were analysed to identify 
enriched pathways and genes differentially regulated with respect to cell growth or 
productivity. While individual studies have suggested these pathways as relevant for CHO cell 
recombinant protein expression, we have established and examined the landscape of 
transcriptomic variability between CHO specific studies. The datasets isolated from these 
studies were aggregated and processed to yield a reduced and manageable number of target 
14 
genes and relevant pathways. This work should prove most useful for those wishing to 
undertake validation studies or trying to mine transcriptomic data from existing CHO cell 
literature as most of the data is not in the same format and not conviently indexable. As a 
result of undertaking this analysis, we have also discovered and highlighted deficiencies in 
currently published transcriptomic studies and suggest improvement to these practices. 
Disclosing the raw data from transcriptomic experiments and using open, non-proprietary 
platforms are key to experiment reproducibility and producing data that is of use to the whole 
community:KLOHSODWIRUPVIRUGHSRVLWLQJDQGDQDO\VLQJGDWDH[LVWVXFKDV1&%,¶V%LRVDPSOH
and Gene Expression Omnibus, they are not widely adopted in bioprocess transcriptomics 
providing unnecessary barriers for transparency of research and utilisation of the data. There 
is also a significant need for an indexed CHO bioprocess omics resource for target selection 
and gene cross-referencing. Projects including the CHO genome project 
(http://www.chogenome.org/) and the CHO co-expression database have already taken the 
first steps toward this goal, however they will rely on the community to provide the required 
data in appropriate depth and format to capture the scope of the CHO omics landscape. While 
new CHO transcriptomic data is regularly being generated using increasingly more 
sophisticated tools and analysis, the curation of data must not be neglected and researchers 
should look to validate results. 
Without presuming lysosomal or cell cycle involvement a priori, through the use of an 
aggregation and frequency based meta-analysis of publicly available transcriptomic data we 
were able to deduce the involvement of these pathways based on the concordance of 
transcriptomic data. Some of the identified targets have already been investigated in 
engineering recombinant CHO cells and validate our meta-study as having predictive value. 
We have yet to see many CHO cell engineering projects in the literature that have been 
informed by transcriptomic studies and this work should prove useful in that regard. 
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Table 1.  List of publications selected for transcriptomic meta-analysis in this study. 
DATABASE ENTRY TITLE TYPE AUTHOR/ 
DATE 
  Predicting cell-specific 
productivity from CHO 
gene expression  
Microarray - 
Wye2aHamster  
Clarke et al14, 2011 
E-GEOD-30321  Gene expression profiling 
of Chinese Hamster 




Clarke et al24, 2011 
E-GEOD-37251  Transcriptomic analysis of 
clonal growth rate 
variation during CHO cell 
line development  
Microarray - 
Wye3aHamster  
Doolan et al13, 2013 
  Microarray and 
proteomics expression 
profiling identifies several 
candidates, including the 
valosin-containing protein 
(VCP), involved in 
regulating high cellular 
growth rate in production 




Doolan et al72, 2010 
  Transcriptome and 
proteome analysis of 
Chinese hamster ovary 
cells under low 
temperature and butyrate 
treatment  
Microarray - Custom-
made Affymetrix® CHO 
Kantardjieff et al16, 2010 
  Translatome analysis of 
CHO cells to identify key 
growth genes  
Microarray - Niblegen 13k 
CHO 
Courtes et al73, 2013 
  Transcriptome and 
proteome profiling to 
understanding the biology 
of high productivity CHO 
cells 
Microarray - 15 K CHO 
cDNA, proteomics 
Nissom et al74,  
2006 
Bioproject 79563  Into the unknown: 
expression profiling 
without genome 
sequence information in 
CHO by next generation 
sequencing.  
Microarray - CHO 
affymetrix; RNAseq 
Birzele et al11, 2010 
  CHO Gene Expression 
Profiling in 
Biopharmaceutical 
Process Analysis and 
Design  
Microarray - CHO 
Affymetrix 
Schaub et al75, 2010 
  Genomic and proteomic 
exploration of CHO and 
hybridoma cells under 
sodium butyrate 
treatment.  
Microarray - CHO cDNA 
library, proteomics 
Yee et al76, 2008 
  Comparative 
transcriptome analysis to 
unveil genes affecting 
recombinant protein 
productivity in mammalian 
cells 
Microarray - CHO cDNA 
library 
Yee et al15, 2009 
19 
  Cell Line Profiling to 
Improve Monoclonal 
Antibody Production  
Microarray - Custom-
made Affymetrix® CHO, 
proteomics 
Kang et al77, 2014 
  Microarray expression 
profiling identifies genes 
regulating sustained cell 
specific productivity (S-
Qp) in CHO K1 
production cell lines  
Microarray - CHO wye2a Doolan et al78, 2012 
  Transcriptome analysis of 
a CHO cell line 
expressing a recombinant 
therapeutic protein 
treated with inducers of 
protein expression  
RNAseq Fomina-Yadlin et al19, 
2015 
  Effect of Temperature 
Downshift on the 
Transcriptomic 
Responses of Chinese 




Production Culture  
RNAseq Bedoya-Lopez et al79, 
2016 
  Cell culture and gene 
transcription effects of 
copper sulfate on Chinese 
hamster ovary cells  
Microarray - Custom-
made Affymetrix® CHO 
Qian et al81, 2011 
  Transcriptomic responses 
to sodium chloride-
induced osmotic stress: A 
study of industrial fed-
batch CHO cell cultures  
Microarray - Custom-
made Affymetrix® CHO 
Shen et al81, 2010 
  Effects of Copper on CHO 
Cells: Insights from Gene 
Expression Analyses  
Microarray - Custom-
made Affymetrix® v3 
CHO; RNAseq 
Yuk et al69, 2014 








Table 2. Frequency analysis results from datasets relating to high growth rate (P) and specific 
productivity (Qp) phenotypes as described in the text. 
  Frequency Concordance 
Gene Name Sum Growth Qp All Growth Qp 
Cd36 CD36 molecule 9 2 7 -0.50 -1.00 -0.33 
Ctsl cathepsin L 8 4 4 -0.43 -0.50 -0.33 
App amyloid beta (A4) precursor protein 7 5 2 -0.67 -0.60 
-
1.00 
Eif6 eukaryotic translation initiation factor 6 7 2 5 0.33 0.00 0.50 
Nedd4 
neural precursor cell expressed, 
developmentally down-regulated 
4 
7 2 5 0.00 1.00 -0.50 
Hnrnpk heterogeneous nuclear 
ribonucleoprotein K 6 4 2 0.60 1.00 
-
1.00 
Lamp1 lysosomal-associated membrane protein 1 6 4 2 -0.60 -0.50 
-
1.00 
Hdgf hepatoma-derived growth factor 6 3 3 0.33 0.33 0.33 
Mcm5 minichromosome maintenance 
complex component 5 6 3 3 0.33 1.00 
-
0.33 




solute carrier family 25 
(mitochondrial 
carnitine/acylcarnitine 
translocase), member 20 
6 3 3 -1.00 -1.00 -1.00 
Eif5a eukaryotic translation initiation factor 5A 6 3 3 0.20 0.33 0.00 
Ldha lactate dehydrogenase A 6 2 4 -0.33 0.00 -0.50 





acyltransferase 2 (mitochondrial 
3-oxoacyl-Coenzyme A thiolase) 
6 0 6 0.33 N/A 0.33 
Glul glutamate-ammonia ligase (glutamine synthetase) 5 4 1 -0.60 -1.00 1.00 
Cbx5 chromobox 5 5 3 2 1.00 1.00 1.00 
Cct3 chaperonin containing Tcp1, 
subunit 3 (gamma) 5 3 2 0.20 1.00 
-
1.00 
Hspa8 heat shock protein 8 5 3 2 0.00 0.33 -1.00 
Kpnb1 karyopherin (importin) beta 1 5 3 2 0.60 1.00 0.00 
Lamp2 lysosomal-associated membrane protein 2 5 3 2 -1.00 -1.00 
-
1.00 
Mcm7 minichromosome maintenance 
complex component 7 5 3 2 0.60 0.33 1.00 
Rsu1 Ras suppressor protein 1 5 3 2 -0.20 -0.33 0.00 
Tuba1b tubulin, alpha 1B 5 3 2 0.50 0.33 1.00 
Retsat retinol saturase (all trans retinol 13,14 reductase) 5 3 2 -1.00 -1.00 
-
1.00 












5 3 2 0.50 1.00 -1.00 
Bsg basigin 5 2 3 -0.20 0.00 -0.33 
Ccnb2 cyclin B2 5 2 3 0.50 0.00 1.00 
Itgb1 integrin beta 1 (fibronectin 
receptor beta) 5 2 3 -0.50 0.00 
-
1.00 
Npc1 NPC intracellular cholesterol transporter 1 5 2 3 -0.50 -1.00 0.00 
Ccl2 chemokine (C-C motif) ligand 2 5 2 3 -0.20 -1.00 0.33 
Cdc20 cell division cycle 20 5 2 3 1.00 1.00 1.00 
Hadhb hydroxyacyl-Coenzyme A dehydrogenase beta subunit 5 2 3 -0.60 -1.00 
-
0.33 
Anxa2 annexin A2 5 1 4 -0.50 1.00 -1.00 
Serpinh1 serine (or cysteine) peptidase inhibitor, clade H, member 1 5 1 4 0.60 1.00 0.50 
Grb2 growth factor receptor bound protein 2 5 1 4 -0.20 1.00 
-
0.50 
Kpna4 karyopherin (importin) alpha 4 5 1 4 -0.20 -1.00 0.00 




Table 3. Frequency distribution of unique genes found in the literature relating to 
transcriptomic changes associated with productivity and growth rate. 
Frequency Sum Growth Qp 
1 3461 1166 3269 
2 918 186 636 
3 283 49 118 
4 81 4 16 
5 25 1 3 
6 10 0 1 
7 3 0 1 
8 1 0 0 





Table 4. Pathway enrichment results from datasets relating to high growth rate (P) and specific 
productivity (Qp) phenotypes as described in the text. Pathways marked with * are non-specfic 
and are only included as a representation of a general enrichment result. High concordance 
values are marked in bold. 
Pathway Count P-Value FE BH p-value FDR Concordance 
Growth 
Cell cycle 15 1.60E-07 6.00 3.00E-05 1.90E-04 0.42 
Phagosome 15 9.40E-06 4.30 9.10E-04 1.20E-02 -0.02 
*Epstein-Barr virus infection 14 3.70E-04 3.20 2.40E-02 4.60E-01 0.55 
Lysosome 10 7.40E-04 4.10 3.50E-02 9.20E-01 -0.73 
*Biosynthesis of antibiotics 13 1.20E-03 3.00 4.60E-02 1.50E+00 0.46 
Specific productivity (Qp) 
Cell cycle 25 5.00E-09 4.1 1.30E-06 6.50E-06 0.15 
*Biosynthesis of antibiotics 32 4.20E-08 3 5.30E-06 5.50E-05 -0.13 
Lysosome 22 3.80E-07 3.7 3.20E-05 4.90E-04 -0.36 
FoxO signaling pathway 20 2.50E-05 3 1.60E-03 3.30E-02 0.18 
Steroid biosynthesis 7 2.10E-04 7.5 8.80E-03 2.70E-01 0.14 
MicroRNAs in cancer 29 1.90E-04 2.1 9.40E-03 2.40E-01 0.11 
Metabolic pathways 89 3.40E-04 1.4 1.20E-02 4.40E-01 -0.12 
Fatty acid degradation 10 5.30E-04 4.1 1.70E-02 6.90E-01 -0.07 
Fatty acid metabolism 10 7.20E-04 4 2.00E-02 9.30E-01 -0.07 







Figure 1. A Venn diagram showing the number of unique genes in both Qp and growth (P) 
categories (A) and the lysosome (B) and cell cycle (C) pathway enrichments.  
 
Figure 2. Pathway enrichment maps for the cell cycle (A) and lysosome pathways (B). Hits 
for the growth group are shown in squares ( ) and the productivity group is represented as 
circles ( ). Overlap between shapes ( ) indicates a hit in the same gene, while adjacent but 
non-overlapping shapes ( ) convey hits in the same gene family. Concordance values for 




Supplementary Excel data spreadsheets 
S1 - Literature annotation table 
S2 - Master gene list containing the frequency of discovered genes across the selected 
publications. 
S3, S4 ± Growth (S3) and Qp (S4) pathway enrichment tables. 
 
